BioWorld

April 7, 2003

Administration Won't Reimburse Failed Project BioShield Drugs

Senior Bush administration officials said companies contracted to develop biomedical countermeasures under Project BioShield would not receive full government payment until the FDA approved their products. (BioWorld Today) Read More

For Biotech, Speaker Declares: 'I've Never Seen A Better Time'

Palindromic DNA Sequence Allows p53 Target Genes To Kill Off Cancer Cells & Suppress Tumor Formation

Deltagen Gains At Least $10M In Private Financing Commitment

Correction

Memantine Improves Cognition When Combined With Aricept

Affymetrix Stock Falls Fast As It Projects Lower Product Revenue

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...